The global genomics market is set to expand from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, with a CAGR of 12.6% ...

The Francis Crick Institute’s flow cytometry core has shown at ELRIG 2025 how a heterogeneous fleet of spectral, mass and ...

A central challenge in relapsed/refractory follicular lymphoma is determining a treatment sequence that maximizes current ...

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

Study links anxiety to 74% fewer natural killer cells—immune defenders against cancer and infections. Insomnia intensifies ...

INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...

To analyze the proteins of neutrophils in sites of inflammation and thus their functional dynamics, it takes millions of these immune cells—a problem, because often only a few cells are found in these ...

Study met its secondary endpoints and demonstrated improvement in biomarkers of collagen turnover, suggesting a resolution of fibrosis and repair of the alveolar basement membrane GRI-0621 ...

Reduced coronary blood flow, measured with an artificial intelligence-based imaging tool, predicted future cardiovascular events in patients with suspected stable coronary artery disease.

First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability ...

GRI Bio (GRI) announced topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic ...

Patient drug sensitivity profiles were linked to their genomic mutation profiles and could provide prognostic and survival data.